NEW YORK, NY / ACCESSWIRE / November 10, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Golar LNG Limited (NASDAQ:GLNG)
CONTACT JAKUBOWITZ ABOUT GLNG:
https://claimyourloss.com/securities/golar-lng-limited-loss-submission-form/?id=10841&from=1
Class Period: April 30, 2020 - September 24, 2020
Lead Plaintiff Deadline: November 23, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) certain employees, including the Chief Executive Officer of Hygo Energy Transition Ltd. f/k/a Golar Power Limited ("Hygo"), had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo's valuation ahead of its initial public offering would be significantly impaired; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Royal Caribbean Cruises Ltd. (NYSE:RCL)
CONTACT JAKUBOWITZ ABOUT RCL:
https://claimyourloss.com/securities/royal-caribbean-cruises-ltd-loss-submission-form/?id=10841&from=1
Class Period: February 4, 2020 - March 17, 2020
Lead Plaintiff Deadline: December 7, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.
Mesoblast Limited (NASDAQ:MESO)
CONTACT JAKUBOWITZ ABOUT MESO:
https://claimyourloss.com/securities/mesoblast-limited-loss-submission-form/?id=10841&from=1
Class Period: April 16, 2019 - October 1, 2020
Lead Plaintiff Deadline: December 7, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law